BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, today announced an oversubscribed $86 million Series B to build the world's largest neurodiagnostic dataset and advance the clinical application of AI-driven biomarkers for brain health. The round was backed by a syndicate of premier healthcare and technology investors, including Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, with continued support from General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. This financing brings Beacon's total funding to more than $121 million.

Unlike consumer wearables that infer brain activity indirectly, Beacon's FDA-cleared Waveband device directly measures the brain's electrical activity (EEG) during sleep and wake, bringing gold-standard neurophysiology out of the lab and into patients' homes. The resulting biosignal data provide ecologically valid, longitudinal measures of brain function across diverse populations. It fuels Beacon's foundation model of brain activity, trained on millions of hours of EEG to uncover early disease signatures and predict treatment response."Our mission is to make brain function measurable and actionable at scale," said Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals. "By training AI on millions of hours of real-world brain data, we're beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated."

With this new investment, Beacon is scaling its technology and operations to accelerate neurobiomarker discovery and broaden clinical adoption. The company's core technology, ...